Business Description
Sinovac Biotech Ltd
NAICS : 325412
SIC : 2834
ISIN : AGP8696W1045
Compare
Compare
Traded in other countries / regions
SVA.USASVQ.Germany Index Membership
NASDAQ Golden Dragon China IndexNASDAQ Golden Dragon China IndexNASDAQ Golden Dragon China IndexNASDAQ Golden Dragon China Index IPO Date
2003-09-26Description
Sinovac Biotech Ltd is a China-based biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including, without limitation, hepatitis A, hepatitis B, hand foot and mouth disease (HFMD) caused by EV71, seasonal influenza, H5N1 and H1N1 pandemic influenza, coronavirus, pneumococcus, poliomyelitis, varicella and mumps.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 32.59 | |||||
| Equity-to-Asset | 0.67 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -15.81 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 1.83 | |||||
| Beneish M-Score | -2.2 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 0.1 | |||||
| 3-Year Book Growth Rate | 152.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 11.39 | |||||
| Quick Ratio | 11.24 | |||||
| Cash Ratio | 10.81 | |||||
| Days Inventory | 1706.67 | |||||
| Days Sales Outstanding | 346.24 | |||||
| Days Payable | 5299.24 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 10.2 | |||||
| Shareholder Yield % | -31.03 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 92.09 | |||||
| Operating Margin % | -84.35 | |||||
| Net Margin % | -29.06 | |||||
| EBITDA Margin % | -4.78 | |||||
| FCF Margin % | -94.31 | |||||
| ROE % | -1.44 | |||||
| ROA % | -0.93 | |||||
| ROIC % | -34.45 | |||||
| 3-Year ROIIC % | -91.56 | |||||
| ROC (Joel Greenblatt) % | -14.52 | |||||
| ROCE % | -1.22 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shiller PE Ratio | 0.83 | |||||
| Price-to-Owner-Earnings | 5.43 | |||||
| PS Ratio | 1.5 | |||||
| PB Ratio | 0.05 | |||||
| Price-to-Tangible-Book | 0.05 | |||||
| EV-to-EBIT | 46.07 | |||||
| EV-to-EBITDA | 337.72 | |||||
| EV-to-Revenue | -16.15 | |||||
| EV-to-FCF | 17.12 | |||||
| Price-to-Projected-FCF | 0.02 | |||||
| Price-to-Median-PS-Value | 0.5 | |||||
| Price-to-Net-Current-Asset-Value | 0.07 | |||||
| Price-to-Net-Cash | 0.07 | |||||
| Earnings Yield (Greenblatt) % | 2.17 | |||||
| FCF Yield % | -87.95 | |||||
| Forward Rate of Return (Yacktman) % | 335.02 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers